Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0
|
作者：
Kozuki, Toshiyuki [1 ]
Nogami, Naoyuki [1 ]
Yamashita, Natsumi [2 ]
Shinkai, Tetsu [3 ]
Shukuya, Takehito [4 ,5 ]
Seki, Nobuhiko [6 ]
Kato, Terufumi [7 ]
Satouchi, Miyako [8 ]
Masuda, Noriyuki [9 ]
Watanabe, Koshiro [10 ]
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan
[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan
[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan
[5] Grad Sch Med, Tokyo, Japan
[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan
[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan
[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan
[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
elderly; Clinical Trial in Progress; NSCLC; bevacizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-085
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [21] Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as first-line treatment for elderly patients with advanced non-squamous non-small cell lung cancer
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Naito, Yoshiko
    Matsuo, Norikazu
    Ichiki, Masao
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results
    Patel, J. D.
    Hensing, T. A.
    Villafor, V.
    Hart, E.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] SAFETY AND RESOURCE USE IN PRONOUNCE: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF PEMETREXED PLUS CARBOPLATIN WITH MAINTENANCE PEMETREXED (PEMC) AND PACLITAXEL PLUS CARBOPLATIN PLUS BEVACIZUMAB WITH MAINTENANCE BEVACIZUMAB (PCB) IN PATIENTS WITH ADVANCED NON-SQUAMOUS (NS) NON-SMALL-CELL LUNG CANCER (NSCLC)
    Ross, Helen J.
    Spigel, David
    Weaver, Robert W.
    Govindan, Ramaswamy
    Holden, Viran
    Chowhan, Naveed M.
    Beck, Thaddeus
    Waterhouse, David
    Modiano, Manuel R.
    Rao, Vijay P.
    Winfree, Katherine B.
    Melemed, Symantha
    Liu, Jingyi
    Koustenis, Andrew G.
    Guba, Susan C.
    Ortuzar, Waldo I.
    Obasaju, Coleman
    Zinner, Ralph
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S578 - S578
  • [24] PHASE II TRIAL OF BEVACIZUMAB PLUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Ohyanagi, F.
    Kudo, K.
    Yanagitani, N.
    Horiike, A.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 441 - 442
  • [25] RANDOMIZED STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN NON-SQUAMOUS NSCLC (LOGIK0904)
    Moriwaki, Atsushi
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    RESPIROLOGY, 2013, 18 : 27 - 27
  • [26] Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
    Fukuda, Minoru
    Kitazaki, Takeshi
    Ogawara, Daiki
    Ichiki, Masao
    Mukae, Hiroshi
    Maruyama, Riichiroh
    Nakagaki, Noriaki
    Shimada, Midori
    Ikeda, Takaya
    Kishimoto, Junji
    Harada, Taishi
    Seto, Takashi
    Ebi, Noriyuki
    Takayama, Koichi
    Okamoto, Isamu
    Ichinose, Yukito
    Sugio, Kenji
    LUNG CANCER, 2019, 132 : 1 - 8
  • [27] Feasibility study of pemetrexed (PEM) plus bevacizumab (BV) as the first-line treatment for elderly advanced or recurrent non-squamous (non-Sq) non-small cell lung cancer (NSCLC): TORG1015
    Kozuki, Toshiyuki
    Nogami, Naoyuki
    Kitajima, Hiromoto
    Shinkai, Tetsu
    Kato, Fumiaki
    Sakaida, Emiko
    Takiguchi, Yuichi
    Ikeda, Satoshi
    Yoshida, Masahiro
    Enomoto, Yasunori
    Kato, Terufumi
    Ogura, Takashi
    Miyamoto, Shingo
    Morita, Satoshi
    Watanabe, Koshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] FEASIBILITY STUDY OF PEMETREXED (PEM) PLUS BEVACIZUMAB (BV) AS THE FIRST-LINE TREATMENT FOR ELDERLY ADVANCED OR RECURRENT NON-SQUAMOUS (NON-SQ) NON-SMALL CELL LUNG CANCER (NSCLC): TORG1015.
    Kozuki, Toshiyuki
    Nogami, Naoyuki
    Kitajima, Hiromoto
    Shinkai, Tetsu
    Kato, Fumiaki
    Sakaida, Emiko
    Takiguchi, Yuichi
    Ikeda, Satoshi
    Yoshida, Masahiro
    Enomoto, Yasunori
    Kato, Terufumi
    Ogura, Takashi
    Miyamato, Shingo
    Morita, Satoshi
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S870 - S870
  • [29] Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.
    Bodor, Joseph Nicholas
    Patel, Jyoti D.
    Ross, Eric A.
    Litwin, Samuel
    Clapper, Margie
    Levy, Benjamin Philip
    Wakelee, Heather A.
    Borghaei, Hossein
    Treat, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] A COST-EFFECTIVENESS ANA LYSIS OF CISPLATIN PLUS PEMETREXED DOUBLET INDUCTION TREATMENT FOLLOWED BY PEMETREXED MAINTENANCE COMPARED WITH BEVACIZUMAB PLUS CISPLATIN PLUS GEMCITABINE TRIPLET INDUCTION TREATMENT FOLLOWED BY BEVACIZUMAB MAINTENANCE FOR NON-SQUAMOUS NSCLC IN SWEDEN
    Bryden, P. A.
    Kumar, G.
    Winfree, K. B.
    Boye, M. E.
    Taipale, K.
    Thompson, R.
    Borgeke, H.
    VALUE IN HEALTH, 2013, 16 (07) : A410 - A410
12345